Previous 10 |
NovoCure ( NVCR ) Q3 results: Revenues: $64.8M (+29.3%); Net Loss: ($11.7M) (+1.7%); Loss Per Share: ($0.13) (unch). More news on: NovoCure, Healthcare stocks news, Earnings news and commentary, Read more ...
NovoCure (NASDAQ: NVCR ): Q3 GAAP EPS of -$0.13 beats by $0.02 . More news on: NovoCure, Earnings news and commentary, Healthcare stocks news, Read more ...
Quarterly net revenues of $64.8 million, representing 29 percent growth versus the third quarter 2017 and 5 percent growth versus the second quarter 2018 Humanitarian device exemption (HDE) application submitted to FDA for approval in malignant pleural mesothelioma Novocure (NASD...
Shares of NovoCure ( NVCR ) were trading at $18/share when I introduced them as "revolutionizing cancer treatment" and at $21/share when I called them a "high conviction" pick. Just a few months later, shares in NovoCure trade comfortably over $45/share and for good reason. NovoCure is see...
Novocure (NASDAQ: NVCR ) and Zai Lab (NASDAQ: ZLAB ) signs an exclusive license agreement for Tumor Treating Fields, including the brand name Optune, in Greater China and a global strategic development collaboration. More news on: NovoCure, Zai Lab Ltd., Healthcare stocks news, ...
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday , September 11. Cramer started the show by remembering the tragic events of Sept. 11, 2001 and the collapse of Lehman Brothers. Despite that, he repeated his mantra, "There is always a bull market ...
Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune®, in China, Hong Kong, Macau and Taiwan Zai Lab will support enrollment of Chinese patients to certain clinical trials investigating Tumor Treating Fields, ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...